X4 Pharmaceuticals, Inc. Common Stock
XFOR Real Time Price USDRecent trades of XFOR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by XFOR's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compositions of cxcr4 inhibitors and methods of preparation and use Oct. 15, 2024
-
Patent Title: Cxcr4 inhibitors and uses thereof Oct. 10, 2023
-
Patent Title: Compositions of cxcr4 inhibitors and methods of preparation and use Jun. 13, 2023
-
Patent Title: Antibodies targeting a galactan-based o-antigen of k. pneumoniae Oct. 11, 2022
-
Patent Title: Methods for treating cancer Jun. 14, 2022
-
Patent Title: Methods for treating cancer May. 24, 2022
-
Patent Title: Cxcr4 inhibitors and uses thereof May. 17, 2022
-
Patent Title: Cxcr4 inhibitors and uses thereof Apr. 19, 2022
-
Patent Title: Methods for treating immunodeficiency disease Jan. 11, 2022
-
Patent Title: Compositions of cxcr4 inhibitors and methods of preparation and use Jun. 29, 2021
-
Patent Title: Cxcr4 inhibitors and uses thereof Apr. 27, 2021
-
Patent Title: Methods for treating cancer Mar. 23, 2021
-
Patent Title: Mdr Mar. 09, 2021
-
Patent Title: Cxcr4 inhibitors and uses thereof Sep. 01, 2020
-
Patent Title: Compositions of cxcr4 inhibitors and methods of preparation and use Feb. 04, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of XFOR in WallStreetBets Daily Discussion
Recent insights relating to XFOR
Recent picks made for XFOR stock on CNBC
ETFs with the largest estimated holdings in XFOR
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view XFOR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.